Tolterodine for the treatment of overactive bladder

被引：6
|
作者：
Salvatore, Stefano [1 ]
Serati, Maurizio [1 ]
Bolis, Pierfrancesco [1 ]
机构：
[1] Univ Insubria, Dept Obstet & Gynecol, Del Ponte Hosp, I-21100 Varese, Italy
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2008年 / 9卷 / 07期
关键词：
antimuscarinic agents; detrusor overactivity; overactive bladder; tolterodine;
D O I：
10.1517/14656560802012494
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background: The overactive bladder syndrome is a common condition affecting similar to 12% of men and women. It is extremely disturbing with a great impact on quality of life. Its treatment involves a combination of behavioural and pharmacological therapy. The latter includes antimuscarinic drugs such as tolterodine. Objective: To review the safety and efficacy of tolterodine in the treatment of overactive bladder in comparison with other available antimuscarinic agents. Methods: A Pubmed search was carried out differentiating randomised, clinical trials; longitudinal, retrospective studies; and metanalysis on the use of tolterodine for overactive bladder treatment. In the comparison with other antimuscarinic agents, only randomised, clinical trials were considered. Results/conclusion: Tolterodine is available as immediate- or extended-release formulations. It has been extensively evaluated with long-term, randomised trials for safety and efficacy showing a significant improvement in overactive bladder symptoms with an excellent tolerability profile.
引用
收藏
页码：1249 / 1255
页数：7
相关论文
共 50 条
  • [21] Efficacy of tolterodine in children with overactive bladder
    Koc, Basak
    Canpolat, Nur
    Adaletli, Ibrahim
    Sever, Lale
    Emir, Haluk
    Caliskan, Salim
    TURK PEDIATRI ARSIVI-TURKISH ARCHIVES OF PEDIATRICS, 2020, 55 (03): : 284 - 289
  • [22] Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder
    Sun, Fengying
    Sui, Cheng
    Zhou, Yulin
    Liu, Ximing
    Shi, Yanan
    Wu, Yi
    Li, Youxin
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 454 (01) : 532 - 538
  • [23] Benefit-Risk Assessment of Tolterodine in the Treatment of Overactive Bladder in Adults
    Alan D. Garely
    Lara Burrows
    Drug Safety, 2004, 27 : 1043 - 1057
  • [24] Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine
    R. A. Appell
    P. Abrams
    H. P. Drutz
    P. E. V. A. Van Kerrebroeck
    R. Millard
    A. Wein
    World Journal of Urology, 2001, 19 : 141 - 147
  • [25] Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine
    Kobelt, G
    Kirchberger, I
    Malone-Lee, J
    BJU INTERNATIONAL, 1999, 83 (06) : 583 - 590
  • [26] Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults
    Garely, AD
    Burrows, L
    DRUG SAFETY, 2004, 27 (13) : 1043 - 1057
  • [27] Twelve-month treatment of overactive bladder - Efficacy and tolerability of tolterodine
    Abrams, P
    Malone-Lee, J
    Jacquetin, B
    Wyndaele, JJ
    Tammela, T
    Jonas, U
    Wein, A
    DRUGS & AGING, 2001, 18 (07) : 551 - 560
  • [28] Socioeconomic burden of urinary incontinence with focus on overactive bladder and tolterodine treatment
    Luscombe, FA
    REVIEWS IN CONTEMPORARY PHARMACOTHERAPY, 2000, 11 (01): : 43 - 62
  • [29] Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis
    Appell, RA
    UROLOGY, 1997, 50 (6A) : 90 - 96
  • [30] The efficacy, tolerability and safety profile of tolterodine in the treatment of overactive/unstable bladder
    Malone-Lee, JG
    REVIEWS IN CONTEMPORARY PHARMACOTHERAPY, 2000, 11 (01): : 29 - 42
12345